Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
All time high.....Huzzah!
Options excercised and replaced with a cash incentive if the Company is sold for more than £85m.
Looks like Company is for sale, just a question of how what price and what timescale.
Good to see the CFO pick up 5,000 shares last month.
Decent buying today!
Trek
CEO statement talks about sales (plural) of DNA!! So revenue has staretd.
Must say looks good. I just put off by spread/liquidity in this market…..
“ FY 2021 results 4basebio’s full-year results to 31 December 2021 reflect consistent progress towards its main objectives, with recently completed clean rooms undergoing validation ahead of targeted DNA production towards the year end. It generated revenues of £0.34m with a pre-tax loss of £3.64m (FY 2020: £0.72m) and ended the period with £9.6m cash, providing it with a cash runway into 2023 and an undrawn loan facility of €25m. When fully operational, this facility will be able to produce DNA with a value in excess of £25m pa and c.80% gross margins. In the meantime, the company continues to build partnerships, with four disclosable agreements signed to date and many that remain under NDAs. We have made changes to forecasts to reflect increased investment in R&D and headcount and reiterate our sum-of-the-parts DCF target price of 1,200p. This is underpinned by the expected high demand for DNA and the significant potential of its technology to address key challenges in the cell and gene therapy space. ”
Usual caveats
Trek
Great RNS
On track and first commercial order confirmed, hopefully more in the months to follow.
Huge vote of confidence in 4BB from Mark Cooper, jumping ship from ABCAM to join 4BB speaks volumes!!
A lot of action today....15 trades unusual.
Hi Scoob
Agree it should be a great year for 4BB.
Fully loaded!!
Lol. Welcome Lightyear. Hoping for an explosive 2022 for 4BB (with watchful eye on Nasdaq)
Hi Guys
Been talking to myself on ADVFN for a while so have come over hear where there appears to be more holders.
I see the CEO bought £30,000 worth in Dec which is a big vote of confidnce and gives me a warm fuzzy feeling!!!!
I see the CE
research- t r e e . c o m
Finncap TP 1200p @ 30/9/21 broker note
Salient details - Finncap noted their rivals Touchlight (synthetic DNA manufacturer with FY 2020 sales of £10.6m which recently extended its private financing round to $125m, and while no available public info is available on valuation, it is estimated to be $500mn.
Can be accessed via
https://*********************/companies/uk/biotechnology/4basebio-plc/research/finncap/4basebio-promising-interims-but-recent-manufacturing-news-is-key-event/8_30899/09ebf110-7367-4058-8302-4b69b26d82a4
Not RNS-ed
Wed, 29th Sep 2021 07:00
4basebio UK Societas - UK-based biotech company - Starts development of its pilot clean room project for the production of DNA. Secures 15-year lease on the 4,400 square foot facility, for GBP50,000 per year. Expects to complete instillation before the end of 2021. Aims for the facility to become operational in the first half of 2022, after testing and validation of the clean room.
Plans to manufacture and sell research and pre-clinical grade DNA for use in gene therapies, while working towards securing good manufacturing practice accreditation. Says that, when fully operational, the facility's seven production suites can generate DNA with a value of up to GBP25 million per annum. Earmarks GBP1.5 million for the project. Notes cash runway into 2023, with ability to draw on its GBP22 million debt facility with its former parent company.
Chief Executive Heikki Lanckriet says: "We are very pleased to have commenced the development of this manufacturing facility, with the objective of taking the final steps in the commercialisation of our DNA technology. Alongside the clear market need for additional DNA manufacturing capacity, our synthetic DNA offers clear advantages over plasmid DNA, which we believe places 4basebio in a strong competitive position."
Current stock price: 710.00 pence
Year-to-date change: up 58% since February 19
By Scarlett Butler; scarlettbutler@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
L2 showing - No shares left literally
Per Finncap March 21 Notes - "4basebio is at the beginning of its valuation journey, and we believe it is
too early to provide a meaningful target price/valuation for the company. There are a
number of comparable companies, albeit more advanced, which provide an indication
of the potential future value. Based on these and discounting back to the present day,
it is possible to envisage the value of its technology rising to c.£75-100m in the near
term (GMP-grade DNA), which compares with its current EV of £26m."
So tightly held any sniff of news and this will double or treble right sector right time.
Spread now 2-3% - even better
Great to see spread now is only 6%
to by 555p to sell 390 WTF !!!!
They are indeed up and running now - free float is very very low it appears and spread is rather wide !
New stock listed today 18th February
why can’t I see 4basebio (4BB) listed with On HL and Trading 212.
Thanks j
Strange one today. Managed to grab a few on iweb. However, availability was very low. So kept quantity on the lower side.
A few hours later, iweb says they do not deal with this share anymore. What? Probably they will rectify themselves soon. Not in a rush to sell. Hope this will do a MXCT!
Guys, any reason why the spread is so wide!
It is not listed on HL tried in the morning but couldnt find and called up the desk but it was a long queue to get through..